Elite Pharmaceuticals, Inc. reported consolidated revenues of $36.3 million for the second quarter of fiscal year 2026 ended September 30, 2025, representing an increase of $17.4 million, or approximately 92%, compared to the same period in the prior fiscal year. Income from operations was $8.2 million, an increase of $4.7 million, or approximately 136%, compared to the comparable period of the prior year. The increase in revenue and income from operations was primarily attributed to sales of Elite's lisdexamfetamine products, which were launched after the prior year's comparable period, as well as overall growth in Elite label product lines. The company will host a conference call to discuss these results and recent business developments.